Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - July 2012

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Adalimumab (Humira®) has been rejected for use in the treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy. The manufacturer failed to make a submission.

Azilsartan (Edarbi®) has been rejected for the treatment of essential hypertension in adults. The manufacturer failed to make a submission.

Azithromycin dihydrate (Azyter®) has been rejected for the local antibacterial treatment of conjunctivitis caused by susceptible strains. The manufacturer failed to make a submission.

Eplerenone (Inspra®) has been accepted for use in addition to standard optimal therapy, to reduce the risk of cardiovascular mortality and morbidity in adult patients with NYHA class II (chronic) heart failure and left ventricular systolic dysfunction (LVEF ≤30%).

Golimumab (Simponi®) has been accepted for restricted use for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate. It can be used alone or in combination with methotrexate when at least two standard DMARDs have failed to provide a response and at the dose of 50mg only.

Tadalafil (Adcirca®) has been accepted for restricted use in the treatment of adults with pulmonary arterial hypertension (PAH) classified as World Health Organisation functional class (WHO-FC) II and III, to improve exercise capacity. The restriction limits treatment initiations to specialists working in the Scottish Pulmonary Vascular Unit or similar specialists.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - July 2012' on Email Share 'SMC Update - July 2012' on Delicious Share 'SMC Update - July 2012' on Digg Share 'SMC Update - July 2012' on Facebook Share 'SMC Update - July 2012' on Google+ Share 'SMC Update - July 2012' on reddit Share 'SMC Update - July 2012' on StumbleUpon Share 'SMC Update - July 2012' on Twitter

atomic-wealth

No Comments to “SMC Update - July 2012”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,657 spam comments.

atomic-wealth
fond-illness
summer